The manufacturers of the Celiac Vaccine that had reached Phase 2 of Clinical Trials decided to end the trial. An interim analysis showed that Nexvax 2, the vaccine to treat Celiac Disease, did not provide enough protection from gluten exposure when compared to placebo. This is on the heels of a presentation at Digestive Disease Week in May that showed Phase1 study to be extremely encouraging.
While disappointing, the data will help inform the other studies in the pipeline. To read more about Celiac Disease research, visit https://www.beyondceliac.org/research/.